Tag: checkpoint inhibitor

Pharmacology News Digest, July 22nd 2018

Continue reading “Pharmacology News Digest, July 22nd 2018”

Advertisements

Checkpoint Inhibitor Combo > Chemo in Some Lung Cancers | NEJM

Non-small cell lung cancer (NSCLC) patients with high tumor mutational burden (>10 mutations/megabase) were selected for a phase III clinical trial comparing combination checkpoint inhibitor therapy to platinum-based chemotherapy.

A combination regimen of Nivolumab, an anti–programmed death 1 (PD-1) antibody, and ipilimumab, an anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody resulted in significantly better 1-year survival (42%) than platinum-doublet chemotherapy (13%).

 

 

Original Article from The New England Journal of Medicine — Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Source: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM